Grant List
Represents Grant table in the DB
GET /v1/grants?sort=awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=awardee_organization", "prev": null }, "data": [ { "type": "Grant", "id": "4728", "attributes": { "award_id": "NNX13AG97G", "title": "DROUGHT ACCOUNTS FOR WIDE SPREAD AGRICULTURAL FAILURE, SIGNIFICANT LOSS OF LIFE THROUGH FAMINE, AND DECLINES IN NATIONAL GDP FOR MANY COUNTRIES, WITH NEARLY 1.9 BILLION PEOPLE HAVING BEEN AFFECTED BY DROUGHT IN THE 20TH C. ACCURATE AND HIGH-RESOLUTION REA", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2013-02-11", "end_date": "2017-02-10", "award_amount": 0, "principal_investigator": { "id": 16385, "first_name": "ERIC", "last_name": "WOOD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "DROUGHT ACCOUNTS FOR WIDE SPREAD AGRICULTURAL FAILURE, SIGNIFICANT LOSS OF LIFE THROUGH FAMINE, AND DECLINES IN NATIONAL GDP FOR MANY COUNTRIES, WITH NEARLY 1.9 BILLION PEOPLE HAVING BEEN AFFECTED BY DROUGHT IN THE 20TH C. ACCURATE AND HIGH-RESOLUTION REA", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9226", "attributes": { "award_id": "75N92020C00034-P00001-9999-1", "title": "RADX-TECH - ELLUME USA, LLC COVID-19 ANTIGEN TEST FOR THE DIRECT DETECTION OF THE SARS COV-2 VIRUS.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-30", "end_date": "2021-09-29", "award_amount": 21470000, "principal_investigator": { "id": 24967, "first_name": "SCOTT", "last_name": "FRY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "A point-of-care, in vitro diagnostic test for the detection of an acute COVID 19 infection for use by healthcare professionals. The test will detect the nucleoprotein antigen of the SARS-CoV-2 virus from a healthcare provider-collected mid-turbinate nasal swab using a hand-held digital platform. The test system is connected to a cloud platform to provide real time access to patient test results by public health authorities for surveillance and monitoring. The test system includes: 1) a single-use test cartridge that connects to the hand-held digital platform 2) a sample collection and processing device 3) a squeezable vial containing a fixed volume of extraction fluid 4) ellume.lab, a hand-held digital platform designed to display test results and provide connectivity to Ellume's cloud. 5) a cloud database and interface for real time data collection, analytics and sharing The test is based on Ellume's established fluorescent immunoassay cartridge with digital detection technology, and leverages a proprietary fluorescence biosensor, with a light signature produced by quantum dot nanoparticles detected and digitized by a highly sensitive but fully disposable optoelectronics package. Ellume.lab, Ellume's digital platform, is a hand-held smart device that can read 2 test cartridges at a time. The device provides a digital user interface and includes step-by-step test instructions, digital interpretation of test results, and is connected to Ellume's cloud platform. The device also connects to the clinic's electronic medical record (EMR) system. The device requires no calibration or maintenance, and is battery operated with over 24 hours use before requiring charging.", "keywords": [ "Acute", "Biosensor", "COVID-19 detection", "Calibration", "Charge", "Clinic", "Computerized Medical Record", "Data Collection", "Databases", "Detection", "Devices", "Fluorescence", "Hand", "Health Personnel", "Health Professional", "Hour", "Immunoassay", "Instruction", "Light", "Liquid substance", "Maintenance", "Monitor", "Nasal turbinate bone structure", "Nucleoproteins", "Patients", "Public Health", "Quantum Dots", "RADx Tech", "SARS-CoV-2 antigen", "SARS-CoV-2 infection", "Step Tests", "System", "Technology", "Test Result", "Testing", "Time", "Vial device", "Virus", "antigen test", "authority", "base", "cloud platform", "design", "detection test", "digital", "in-vitro diagnostics", "nanoparticle", "nasal swab", "point of care", "sample collection" ], "approved": true } }, { "type": "Grant", "id": "4696", "attributes": { "award_id": "NNX15AB58G", "title": "THE PECORA 19 SYMPOSIUM IN CONJUNCTION WITH THE JOINT SYMPOSIUM OF ISPRS TECHNICAL COMMISSION I AND IAG COMMISSION 4 MULTI- DAY EVENT WILL INCLUDE TECHNICAL PROGRAMS, PLENARY SESSIONS WITH KEYNOTE AND INVITED PAPERS, AND PARALLEL SESSIONS WITH ORAL AND PO", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2014-10-29", "end_date": "2015-04-28", "award_amount": 0, "principal_investigator": { "id": 16283, "first_name": "MICHAEL", "last_name": "HAUCK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "THE PECORA 19 SYMPOSIUM IN CONJUNCTION WITH THE JOINT SYMPOSIUM OF ISPRS TECHNICAL COMMISSION I AND IAG COMMISSION 4 MULTI- DAY EVENT WILL INCLUDE TECHNICAL PROGRAMS, PLENARY SESSIONS WITH KEYNOTE AND INVITED PAPERS, AND PARALLEL SESSIONS WITH ORAL AND PO", "keywords": [], "approved": true } }, { "type": "Grant", "id": "4446", "attributes": { "award_id": "NNX15AL42G", "title": "THE OBJECTIVES OF OUR PROPOSED WORK ARE, I. TO DERIVE SPATIAL AND TEMPORAL VARIATIONS OF TITAN''S SURFACE TEMPERATURE BY ANALYSIS OF THE MOON''S OUTGOING RADIANCE AROUND 19 M (530 CM 1); (II) TO COMPARE THE RESULTS TO PREDICTIONS FROM AN ATMOSPHERIC GENE", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2015-05-26", "end_date": "2017-05-25", "award_amount": 0, "principal_investigator": { "id": 15205, "first_name": "VALERIA", "last_name": "COTTINI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "THE OBJECTIVES OF OUR PROPOSED WORK ARE, I. TO DERIVE SPATIAL AND TEMPORAL VARIATIONS OF TITAN''S SURFACE TEMPERATURE BY ANALYSIS OF THE MOON''S OUTGOING RADIANCE AROUND 19 M (530 CM 1); (II) TO COMPARE THE RESULTS TO PREDICTIONS FROM AN ATMOSPHERIC GENE", "keywords": [], "approved": true } }, { "type": "Grant", "id": "4877", "attributes": { "award_id": "NNX11AG68G", "title": "The U.S. Antarctic Meteorite Program has been one of the most successful endeavors in the history of meteoritics and planetary science. Through the 2009-2010 field season, -19,700 meteorites have been recovered. These meteorites have produced fundamental", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2011-01-03", "end_date": "2017-06-30", "award_amount": 0, "principal_investigator": { "id": 16929, "first_name": "CATHERINE", "last_name": "CORRIGAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The U.S. Antarctic Meteorite Program has been one of the most successful endeavors in the history of meteoritics and planetary science. Through the 2009-2010 field season, -19,700 meteorites have been recovered. These meteorites have produced fundamental", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8098", "attributes": { "award_id": "75N92021C00003-0-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROJECT #6139: REVOGENE SARS-COV-2 ASSAY", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-01", "end_date": "2022-01-31", "award_amount": 5505000, "principal_investigator": { "id": 23980, "first_name": "TODD", "last_name": "WOODRICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Resubmission of Application 3136. This product concept has been updated to include Flu viral targets along with SARS-CoV-2. The Rapid Acute Respiratory Panel assay will be a molecular IVD assay practiced on an already deployed automated Revogene instrument which currently has 4 infectious disease FDA cleared assays. The intended use will be to detect the Flu A, Flu B and SARS-CoV-2 viruses from nasopharyngeal specimens collected from symptomatic patients suspected of viral infection. This will be a multiplexed viral panel for the differentiation of Flu from SARS-CoV-2 patients which will be of high clinical value in our upcoming Flu season 2020-2021. We plan to launch this assay with EUA status by October 2020. The assay will detect RNA sequences for these viral targets using PCR amplification technology coupled with real-time flourescence detection similar to our FDA cleared assays. The workflow is automated where the user will need to add the specimen to the assay consumable prior to loading on the instrument. The Revogene platform contains the necessary software to run the assay and report out positive/negative results. This assay is of very low complexity to practice with no precision pipetting steps and is eligible for CLIA waiver status. We currently have an installment base of instruments in the field where this assay will be practiced. For this product concept, we will need your assistance in discussing this concept with the FDA to allow us to gain EUA and CLIA waiver status especially for the Flu A/B targets in the panel.", "keywords": [ "2019-nCoV", "Acute", "Biological Assay", "COVID-19 assay", "COVID-19 patient", "Clinical", "Communicable Diseases", "Computer software", "Coupled", "Detection", "Molecular", "Patients", "RADx Tech", "RNA Sequences", "Reporting", "Running", "Seasons", "Specimen", "Technology", "Time", "Update", "Viral", "Virus", "Virus Diseases", "base", "betacoronavirus", "flu", "instrument", "respiratory", "waiver" ], "approved": true } }, { "type": "Grant", "id": "8122", "attributes": { "award_id": "75N92021C00009-0-9999-1", "title": "RADX TECH XTRAVA, INC. - SPERA COVID-19 AG TESTRAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT #5834 XTRAVA, INC.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-03-04", "end_date": "2022-03-03", "award_amount": 6207000, "principal_investigator": { "id": 23997, "first_name": "SAMEH", "last_name": "SARHAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Mitigating the economic and health challenges of COVID-19 is hindered by the absence of mass population testing. Available platforms are designed for lab-use and rely on sophisticated technologies and readers. They are slow, expensive, hard to manufacture and overload healthcare professionals with time consuming manual workflows; presenting massive obstacles to high throughput testing. We introduce a novel platform to diagnose COVID-19, which includes a digital test that combines fluorescent lateral flow assays with our patent-pending cost-optimized lateral flow test platform which was initially developed to detect H1N1. We have formed the essential alliances with key partners to rapidly scale up manufacturing and distribution to the points-of-need. Nasal swabs (and soon saliva samples) are tested in under 15 minutes. The digital results are wirelessly communicated to the participants’ mobile devices and the cloud thereby providing healthcare providers with test status and sharing real-time analytics and monitoring capabilities with health authorities. In the first stage, the test will be deployed into CLIA-waived point-of-care clinics, walk-in facilities and drive-thru testing centers for less than $35 for the digital test and with an effective cost of less than $10 per disposable test. After full validation, we will immediately extend deployment to at-home use by leveraging machine vision-guided self-testing. By combining IoT technologies that are proven to enable large-scale production with rapid diagnostic testing we believe we are uniquely positioned to increase testing throughput by 10X-100X. RADx re-enforcement will propel the launch of the system in highly condensed timeframes to meet the enormous need.", "keywords": [ "Acceleration", "COVID-19", "COVID-19 diagnosis", "Clinic", "Consumption", "Diagnostic", "Diagnostic tests", "Economics", "Health", "Health Personnel", "Health Professional", "Home", "Influenza A Virus H1N1 Subtype", "Legal patent", "Manuals", "Monitor", "Population", "Positioning Attribute", "RADx", "RADx Tech", "Rapid diagnostics", "Reader", "System", "Technology", "Testing", "Time", "Validation", "Walking", "Wireless Technology", "authority", "cost", "design", "digital", "handheld mobile device", "large scale production", "lateral flow assay", "machine vision", "manufacturing scale-up", "nasal swab", "novel", "point of care", "programs", "saliva sample", "self testing" ], "approved": true } }, { "type": "Grant", "id": "11681", "attributes": { "award_id": "1U01DA057849-01", "title": "Supported employment to create a community culture of SARS-CoV-2 rapid testing among people who inject drugs: PeerConnect2Test", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": null, "end_date": null, "award_amount": null, "principal_investigator": { "id": 26966, "first_name": "Camille C", "last_name": "Cioffi", "orcid": "https://orcid.org/0000-0003-2424-7473", "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "['psi.uoregon.edu']", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9115", "attributes": { "award_id": "75N92020C00010-P00001-9999-1", "title": "RADX TECH - TALIS BIOMEDICAL HIGHLY SCALABLE SARS-COV-2 RNA DETECTION IN MINUTES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-07-29", "award_amount": 9750000, "principal_investigator": { "id": 24901, "first_name": "JENNIFER", "last_name": "BALDWIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "With over $100M investment by the top biotech Venture Capital funds, NIH, CARB-X, and DARPA, Talis has developed ultrafast, sensitive, scalable technology uniquely suitable for COVID-19 testing. The Talis technology performs rapid (as fast as 6 minutes) purification of SARS-CoV-2 RNA from large volumes of human specimens including swabs and saliva and detects SARS-CoV-2 RNA in under 5 minutes for high positives and under 10 minutes near the limit of detection (~10 copies/reaction). Talis will deploy this technology in a high-throughput format for laboratories (Talis HT) and at the point-of-care (POC) for minimally trained users (Talis One). With RADx support, Talis will scale this technology in three stages: (1) In June, to accelerate throughput of the currently installed diagnostic equipment, Talis will deliver reagent kits for rapid SARS-CoV-2 detection in 96-well format. (2) In July, to further increase testing throughput, Talis will launch automation solutions for common diagnostic laboratory platforms, making kits for 4 million tests available. (3) In September, Talis will launch its rapid COVID-19 Talis One POC test on a multiplexed cartridge, expandable to include influenza. Operated by a compact Talis One instrument, this cartridge enables fully automated, sensitive SARS-CoV-2 RNA detection in under 20 minutes. Talis HT and Talis One will be adaptable to mobile testing for rapid response contact tracing, worker screening, and outbreak response. Talis is requesting RADx support to scale up and accelerate manufacturing of tests and will commit significant funds for cost-sharing.", "keywords": [ "2019-nCoV", "Automation", "Biotechnology", "COVID-19", "COVID-19 detection", "COVID-19 testing", "Capital Financing", "Contact Tracing", "Cost Sharing", "Detection", "Diagnostic", "Diagnostic Equipment", "Disease Outbreaks", "Funding", "Human", "Influenza", "Investments", "Laboratories", "RADx", "RADx Tech", "RNA", "Reaction", "Reagent", "Saliva", "Specimen", "Swab", "Technology", "Testing", "Training", "United States National Institutes of Health", "detection limit", "instrument", "point of care", "point of care testing", "rapid testing", "response", "scale up", "screening" ], "approved": true } }, { "type": "Grant", "id": "8834", "attributes": { "award_id": "75N95021P00635-0-0-1", "title": "Acquisition of Smile CDR FHIR-based clinical data repository Software. FY21 procurement.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-27", "end_date": "2022-09-26", "award_amount": 174000, "principal_investigator": { "id": 24646, "first_name": "CLEMENT", "last_name": "NG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The NCATS National COVID Cohort Collaborative (N3C) Data Enclave, a centralized and secure data platform featuring powerful analytics capabilities for online discovery, visualization and collaboration for researchers studying COVID-19. The data are robust in scale and scope and are transformed into a harmonized data set to help scientists study COVID 19, including potential risk factors, protective factors and long-term health consequences. The N3C Data Enclave is anticipated to be one of the largest collections of data on COVID-19 patients in the United States. Data analysis within the enclave is supported by both R and Python, the most widely used open-source platforms for statistical analysis and data science. Researchers requesting access to, or working within, the enclave are encouraged to assemble collaborative teams with diverse expertise in such areas as clinical research, statistical analysis and informatics to make the best use of the N3C Data Enclave. A core tenet of the enclave is that it is both accessible and secure, allowing researchers to pursue research in a safe environment conducive to collaborative discovery while also allowing for the deployment of a wide variety of open source tools and components.", "keywords": [ "Area", "COVID-19", "COVID-19 patient", "Clinical Research", "Collaborations", "Data", "Data Analyses", "Data Collection", "Data Science", "Data Set", "Environment", "Fast Healthcare Interoperability Resources", "Health", "Informatics", "Pythons", "Research", "Research Personnel", "Risk Factors", "Scientist", "Secure", "Smiling", "Statistical Data Interpretation", "United States", "Visualization", "base", "clinical data repository", "cohort", "coronavirus disease", "data enclave", "data harmonization", "open source", "open source tool", "protective factors", "software repository" ], "approved": true } } ], "meta": { "pagination": { "page": 1, "pages": 1424, "count": 14236 } } }